Evaluation of Metionac for the Modulation of Metabolic and Endocrine Parameters in Patients With PCOS.

NCT05340634 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Polycystic Ovary Syndrome

Interventions

DIETARY_SUPPLEMENT: Metionac
DRUG: Oral contraceptive

Sponsor

Margan Biotech

Collaborators

[object Object]